Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase 2 Study to Evaluate Safety and Efficacy of the Combination of SHR-1210 With Capecitabine + Oxaliplatin or Apatinib as First-line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Next Previous
Trial Profile

A Randomized Phase 2 Study to Evaluate Safety and Efficacy of the Combination of SHR-1210 With Capecitabine + Oxaliplatin or Apatinib as First-line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camrelizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary) ; Rivoceranib (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Sponsors Jiangsu Hengrui Medicine Co.

Most Recent Events

  • 24 Aug 2021 Status changed from active, no longer recruiting to completed.
  • 25 Mar 2021 Results assessing (n=48; Cohort 1; between 2 Apr 2018 and 13 Nov 2018; cutoff date 29 Feb, 2020) efficacy and safety of camrelizumab in combination with CAPOX followed by camrelizumab plus apatinib as first-line combination regimen for advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, published in the Clinical Cancer Research.
  • 28 Apr 2020 Planned End Date changed from 30 Dec 2019 to 30 Dec 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top